Physician profile
Sarah Nicole Harrod
NPI 1366129587
$4,244.78
in general payments reported to CMS, 2019-2025
20 companies · $4,245 in 2025
The $4,245 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,074 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,074.30 |
| Education | $170.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $525.06 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $465.58 | 2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $433.54 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $426.33 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $346.38 | 2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $343.92 | 2025 | Fanapt |
| Alkermes, INC. | $332.31 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $289.41 | 2025 | Rexulti |
| Abbvie INC. | $265.38 | 2025 | |
| Axsome Therapeutics, INC. | $212.12 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $152.44 | 2025 | Xelstrym |
| Biogen, INC. | $98.85 | 2025 | Zurzuvae |
| Braeburn INC. | $84.90 | 2025 | Brixadi |
| Indivior INC. | $68.01 | 2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $61.18 | 2025 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $38.19 | 2025 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $36.23 | 2025 | Cobenfy |
| Lilly USA, LLC | $27.79 | 2025 | Zepbound |
| Collegium Pharmaceutical, INC. | $22.90 | 2025 | Jornay Pm |
| Corium, LLC | $14.26 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Harrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.